STOCK TITAN

Bristol-Myers Squibb Co. - BMY STOCK NEWS

Welcome to our dedicated news page for Bristol-Myers Squibb Co. (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bristol-Myers Squibb Co.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bristol-Myers Squibb Co.'s position in the market.

Rhea-AI Summary
Bristol Myers Squibb (BMY) announces that the FDA has accepted the sBLA for Breyanzi to expand its indication to include treatment for adult patients with relapsed or refractory CLL or SLL. The FDA has granted the application Priority Review and assigned a PDUFA goal date of March 14, 2024. The application is based on results from the TRANSCEND CLL 004 study, which demonstrated deep and durable efficacy of Breyanzi. If approved, it would be the first and only CAR T cell therapy available for this patient population, addressing a critical unmet need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.83%
Tags
none
-
Rhea-AI Summary
Tempus (NYSE: TMPS) announces strategic research collaboration with Bristol Myers Squibb to accelerate cancer research and treatment options using AI, multimodal datasets, and patient-derived disease models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
AI
-
Rhea-AI Summary
Bristol Myers Squibb will present new clinical trial data and real-world analyses of CAMZYOS® (mavacamten) at the American Heart Association's annual Scientific Sessions. The data includes new analyses of the effectiveness of CAMZYOS in patients with and without gene variants, as well as real-world analyses of patients with symptomatic obstructive hypertrophic cardiomyopathy receiving CAMZYOS in clinical practice. The Bristol Myers Squibb-Pfizer Alliance will also present data on oral anticoagulant utilization patterns among patients with non-valvular atrial fibrillation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
conferences
Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) will present research at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. Results from 73 data disclosures, including 22 oral presentations, will be featured, showcasing their commitment to transformative medicines for blood disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
none
-
Rhea-AI Summary
Bristol Myers Squibb (BMY) will participate in the 2023 UBS BioPharma Conference in Miami Beach, Florida, on November 8, 2023. Lynelle Hoch, president of the cell therapy organization, will answer questions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
conferences
-
Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) appoints Boerner as CEO, Caforio to retire as Chair after 23 years
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
management
Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) has priced a public offering of senior unsecured notes in a combined aggregate principal amount of $4.5 billion. The notes will be issued in four tranches with varying interest rates and maturity dates. The offering is expected to close on November 13, 2023. The net proceeds will be used for general corporate purposes, including the financing of the proposed acquisition of Mirati Therapeutics, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
-
Rhea-AI Summary
Karyopharm Therapeutics has entered into a clinical trial collaboration and supply agreement with Bristol-Myers Squibb to evaluate the combination of mezigdomide and selinexor in patients with relapsed/refractory multiple myeloma. The trial will assess the combination in patients who have prior exposure to certain drug agents and have received at least two prior lines of therapy. The trial is expected to be initiated in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
clinical trial
-
Rhea-AI Summary
Karyopharm Therapeutics has entered into a clinical trial collaboration and supply agreement with Bristol-Myers Squibb to evaluate the combination of mezigdomide and selinexor in patients with relapsed/refractory multiple myeloma. The trial will assess the combination in patients who have prior exposure to certain drug agents and have received at least two prior lines of therapy. The trial is expected to be initiated in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
clinical trial
Rhea-AI Summary
Bristol Myers Squibb's type II variation application for Opdivo in combination with cisplatin-based chemotherapy for the treatment of urothelial carcinoma has been validated by the EMA. The application is based on the Phase 3 CheckMate -901 trial, which showed statistically significant and clinically meaningful survival benefit over standard-of-care cisplatin-based chemotherapy. Opdivo and Opdivo-based combinations have demonstrated improvements in overall survival in Phase 3 clinical trials across multiple tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
none
Bristol-Myers Squibb Co.

NYSE:BMY

BMY Rankings

BMY Stock Data

109.66B
2.02B
0.1%
79.18%
1.84%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About BMY

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.